Alabama Board of Nursing Defense Attorney – Hearing Defense. Call today for details about your nursing matter – FDA approves new treatment for advanced pancreatic cancer – (866) 348-2889

The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

The approval came Oct. 22 after Onivyde had been given Priority Review status and an orphan drug designation by the FDA, according to a news release. Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation provides incentives such as tax credits, user fee waivers, and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases.